Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemis
| Condition(s) | Small Intestinal Bacterial Overgrowth Syndrome (SIBO) |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. This study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital |
| Who can participate | Inclusion Criteria: * Adults 18 years of age or older * IBS-SSS score \>175 * Meets North American Consensus criteria for H2 SIBO * Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks * Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test * Willing to have three blood drawstests and fast overnight before the draw * Able to speak, read, and understand English * Able to provide informed consent * For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled Exclusion Criteria: * Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test * Initiation of change in diet, medication, or |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | National University of Natural Medicine |
| Locations | Portland, Oregon, United States |
| Start date | 2025-01-01 |
| NCT ID | NCT06721884 |
| Official listing | https://clinicaltrials.gov/study/NCT06721884 |